• Metformin should only be considered where intensive lifestyle modifications for 3 to 6 months have not resulted in adequate glycaemic control. No prospective comparative data for metformin on macrovascular outcomes in patients with IGT and/or IFG and/or increased HbAPublished risk factors for type 2 diabetes include: Asian or black ethnic background, age above 40, dyslipidaemia, hypertension, obesity or being overweight, age, 1st degree family history of diabetes, history of gestational diabetes mellitus, and polycystic ovary syndrome (PCOS).Consideration must be given to current national guidance on the definition of prediabetes.Patients at high risk should be identified by a validated risk-assessment tool.The prospective randomised (UKPDS) study has established the long-term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin as first-line therapy after diet failure. These tablets are manufactured by Franco Indian Pharmaceuticals Pvt. The mean Vd ranged between 63-276 L.Metformin is excreted unchanged in the urine. However, the dosage may vary with the severity of the ailment to be treated. If necessary, adjust the metformin dosage during therapy with the other drug and upon its discontinuation.Metformin is a substrate of both transporters OCT1 and OCT2. One must not increase or decrease the dosage without consulting the doctor.

Docprime is solely a technology partner. Patients are advised to maintain a strict exercise and diet regimen along with this medicine to get the best possible effect. Mentioned below are some of the medicines that may react with Glyciphage 500 MG Tablet, they are: • In patients already treated with metformin tablets, the starting dose of Glucophage SR should be equivalent to the daily dose of metformin immediate release tablets. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.Hypoglycaemia has not been seen with metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances.

When such people use Glyciphage, it should be used with extra care and caution. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5. A similar action has not been demonstrated with the prolonged release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.The mean baseline values of the DPP participants (n=3,234 for 2.8 years) were age 50.6±10.7 years, 106.5±8.3 mg/dl fasted plasma glucose, 164.6±17.0 mg/dl plasma glucose two hours after an oral glucose load, and 34.0±6.7 kg/mThe advantage of the lifestyle intervention over metformin was greater in older persons.The patients who benefited most from the metformin treatment were aged below 45 years, with a BMI equal or above 35kg/mTo prevent one case of overt diabetes during the three years in the whole population of the DPP, 6.9 patients had to participate in the intensive lifestyle group and 13.9 in the metformin group. It is advisable to store the medicine in a cool and dry place, away from the reach of children and pets. In patients treated with metformin at a dose above 2000 mg daily, switching to Glucophage SR is not recommended. It

For diabetes it is recommended that insulin should be used to maintain blood glucose levels as close to normal as possible to reduce the risk of malformations of the foetus.Metformin is excreted into human breast milk. High overdose or concomitant risks of metformin may lead to lactic acidosis. Glyciphage 500 MG Tablet SR is an effective first choice medicine used to control high blood glucose levels in patients with type II diabetes. • The usual starting dose is one tablet of Glucophage SR 500 mg once daily.